NewsRoom Articles - Page 2 of 63

FridayApr 10, 2026 9:00 am

Rail Vision Ltd. (NASDAQ: RVSN) Positions AI-Powered Collision Avoidance Tech as Solution to Rail Safety Mandates

The National Transportation Safety Board (“NTSB”) has intensified its focus on collision-prevention technologies following multiple rail incidents. Rail Vision’s proprietary sensor systems are designed to address key railway safety challenges by combining advanced imaging technologies with artificial intelligence and deep learning algorithms. The company’s technology is also designed to integrate with existing rail infrastructure, providing flexibility for operators seeking to upgrade safety capabilities without requiring extensive system overhauls. Rail-safety regulators are increasingly calling for advanced collision-avoidance systems as rail networks grow more complex, and Rail Vision’s (NASDAQ: RVSN, FSE: C80) artificial-intelligence (“AI”)-powered electro-optical sensors are emerging as a direct technological…

ThursdayApr 09, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments The company recently strengthened its position through a strategic partnership with Liora Technologies and the expansion of clinical trials These developments highlight Lixte’s broader mission: To improve cancer outcomes through innovation, combination-based therapeutic strategies Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with its…

WednesdayApr 08, 2026 10:00 am

Block Co-Founder Foresees AI Doing Middle Management Tasks

Jack Dorsey is making a concrete bet that artificial intelligence can replace what middle managers have done in large organizations for generations. Block’s chief executive, writing jointly with lead independent director Roelof Botha, has outlined a structural transformation in which AI takes on work currently handled by layers of human management. That means moving information, tracking progress and generating real-time operational visibility across the entire business, without a manager in the middle. The case they make starts with a critique of hierarchy itself. Management layers were designed to solve an information problem. In large organizations, someone has to gather data, relay it upward and translate decisions back down. Dorsey and Botha believe…

WednesdayApr 01, 2026 10:00 am

Researchers Solve 50-Year-Old Challenge in Making Cancer Drug

Scientists have overcome production barriers that have plagued doxorubicin manufacturing since the 1970s by engineering bacteria that generate 180% more of the critical chemotherapy drug than current methods achieve. The breakthrough addresses molecular bottlenecks that forced pharmaceutical companies to rely on expensive, multi-step processes despite treating over one million cancer patients annually with the medication. The advance could reshape how essential medicines get produced globally. Doxorubicin has been essential to the treatment of breast cancer, bladder cancer, lymphomas, and carcinomas since gaining approval five decades ago. However, bacteria that naturally synthesize the compound do so extremely inefficiently, creating supply constraints…

TuesdayMar 31, 2026 11:15 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”). LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer’s internal repair system. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far. LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.…

MondayMar 30, 2026 10:00 am

Research Suggests the Thymus is Critical in Immunotherapy Outcomes

Cancer patients with healthier thymus glands show dramatically better responses to immunotherapy, cutting progression risks by roughly one-third and death risks by nearly half compared to those with weaker thymic function. New research leveraging artificial intelligence to evaluate chest scans challenges medical assumptions that dismissed this immune organ as irrelevant past childhood, revealing it may determine who benefits from modern cancer treatments that are dependent on robust immune systems. Separate research tracking over 27,000 adults found those with stronger thymic function lived longer while experiencing half the premature mortality, one-third fewer cardiovascular deaths, and substantially reduced lung cancer development versus people showing poorer thymic health on imaging. Hugo Aerts from Harvard Medical School and Dana-Farber Cancer Institute,…

MondayMar 30, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance tumor response to treatment. LIXTE’s LB-100 is designed to sensitize cancer cells to chemotherapy and potentially enhance immune system activity, offering a complementary approach to existing treatments. The company recently announced the expansion of its ongoing clinical trial in clear cell ovarian cancer, including an increase in patient enrollment that effectively doubles the size of the study. Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need…

ThursdayMar 26, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectiveness of established cancer treatments while cutting down toxicity Strategic partnership with Liora Technologies integrates multimodal oncology data, enabling precision-guided patient care and streamlined clinical trials These developments position the company at the intersection of innovation and therapeutics Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side…

WednesdayMar 25, 2026 10:00 am

Political Campaigns Start Featuring Ads Created Using AI

Artificial intelligence has moved from a background tool into a visible presence in American political advertising and its arrival is generating real friction well ahead of the 2026 midterm cycle. Campaign teams at every level of electoral competition are finding ways to work it into their advertising, but unfortunately, it's not always in ways that voters would recognize as synthetic. The case drawing the most attention comes from Massachusetts. A Republican primary campaign produced a radio spot featuring a machine-generated voice crafted to sound like Democratic Governor Maura Healey, articulating positions she has no record of taking. Both videos portrayed…

TuesdayMar 24, 2026 9:45 am

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation Proton therapy's ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000